The shift from fully integrated pharmaceutical companies (FIPCOs) to virtually integrated pharma companies (VIPCOs) has made biopharmas more reliant on…
Baxalta Incorporated, a $6 billion global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved…
AstraZeneca's global biologics R&D arm MedImmune has entered into a five-year multi-project research collaboration with the University of Sheffield to…
Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA),…